Join AbbVie for their upcoming National Broadcast: New Evidence in First-Line AML and Exploring Outcomes with Fixed-Duration Treatment in CLL, taking place on Thursday, 11/12 and Tuesday, 11/17 across multiple time zones. These educational events are in support of oncologists and care teams. You may tailor the program to your audience by selecting to have the data delivered by MDs or APPs.
Attendees will have the opportunity to learn directly from experts in AML and CLL. During this interactive presentation we will:
- Recognize VENCLEXTA as a BCL-2 inhibitor for 1L AML, and 1L and R/R CLL
- Review the phase 3 efficacy and safety outcomes of VENCLEXTA + azacitidine from the pivotal VIALE-A study for patients with 1L AML, ineligible for intensive induction chemotherapy due to age or comorbidities
- Explore the efficacy and safety outcomes of VENCLEXTA’s chemo-free, fixed duration CLL regimens
Please see the attached invitation with details and registration can be made via the links on the attached invitation or via your AbbVie representative.